Curis, Inc.

Curis, Inc. is a biotechnology company whose core business model involves developing cancer therapeutics. The company's drug development pipeline necessitates extensive animal testing as part of preclinical research and regulatory compliance. In its public disclosures, Curis explicitly acknowledges conducting long-term preclinical animal tests, including studies for reproductive adverse events and carcinogenicity, which are standard requirements for FDA approval of new drugs.

The evidence gathered indicates that animal testing is an integral and unavoidable component of Curis's operations. While the specific scale and numbers of animals used are not detailed in the available public filings, the nature of its business in oncology drug development implies a reliance on in vivo models to assess drug efficacy and safety. This places the company's activities under the general animal_exploitation exclusion category, as the testing is conducted for commercial development purposes and is not covered by a more specific child code.